Veritas Pharma Inc (CSE: VRT), a Vancouver-based pharmaceutical company, announced today that the company has named Whistler Medical Marijuana Corp. as its principal supplier of cannabis cultivars. Veritas will purchase cannabis cultivars from Whistler, whom is licensed by Health Canada to produce dried or fresh marijuana as well as cannabis oil, over the next 18 months and supply it to Cannevert Therapeutics Ltd. for preclinical and clinical testing.
"The variety of cannabis that Whistler has to offer will ensure that Cannevert will have the best quality and quantity of material needed to conduct research,” said Dr. Lui Franciosi, CEO of Veritas Pharma.
Furthermore, Veritas Pharma has appointed Jesse McConnell, the co-founder of Whistler Medical Marijuana, along with Peter Doig and Peter Smith to its new advisory board. Doig is a Professional Agrologist, specializing in converting conventional agricultural systems over to certified organic practices without compromising product yield or quality. Smith is a lawyer with over 10 years' experience as a CEO and/or director of TSX-V listed companies.
Veritas Pharma is focused on using their knowledge to streamline the development of cannabis-based treatments to capture considerable market share. Developing innovative medicinal cannabis cultivars for specific disease conditions such as chronic pain, nausea, and epilepsy, the company has announced a number of positive milestones in achieving their operational goals. These milestones include:
- Appointing Dr. Domenico Spina as a director of the company.
- Its wholly owned subsidiary, Sechelt Organic Marijuana Corp., Veritas Pharma applying to Health Canada for a medical marijuana production and distribution license under the Marihuana for Medical Purposes Regulations.
Furthermore, in January, the company announced the appointment of David Alexander as CFO.
Veritas continues to move their goals forward through strategic partnerships and further strengthening their leadership team. With these positive announcements, the company further positions themselves as a major player in the cannabis sector. “Having Whistler's co-founder, Jesse McConnell advising us on the best genetics to examine, based existing patient feedback, will help us streamline our focus,” said McConnell, “we are also excited to have Peter Doig and Peter Smith to provide guidance on the strategic growth of our company in this industry."
For more information about Veritas Pharma, visit www.veritaspharmainc.com.
In the interest of full disclosure, we call the reader's attention to the fact that Equities.com, Inc. has been compensated 137,500 common shares plus warrants by Veritas Pharma, Inc. for its profile in the Spotlight Companies section. The purpose of these profiles is to provide awareness of these companies to investors in the micro, small-cap and growth equity community and should not in any way be considered as a recommendation to buy, sell or hold these securities. Equities.com is not a registered broker dealer, investment advisor, financial analyst, investment banker or other investment professional. We are a publisher of original and third party news and information. All profiles are based on information that is available to the public. The information contained herein should not be considered to be complete and is not guaranteed by Equities.com to be free from misstatement or errors. The views expressed are our own and not intended to be the basis for any investment decision. Readers are reminded to do their own due diligence when researching any companies mentioned on this website. Always bear in mind that investing in early-stage companies is risky and you are encouraged to only invest an amount that you can afford to lose completely without any change in your lifestyle.
DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer